Dataset Information


SK-216, a Novel Inhibitor of Plasminogen Activator Inhibitor-1, Suppresses Lung Metastasis of Human Osteosarcoma.

ABSTRACT: Lung metastasis constitutes the leading cause of the death in patients with osteosarcoma. We have previously reported that plasminogen activator inhibitor-1 (PAI-1) regulates the invasion and lung metastasis of osteosarcoma cells in a mouse model and as well as in clinical samples. In the present study, we examined the anti-metastatic effect of SK-216, a small compound PAI-1 inhibitor, in human 143B osteosarcoma cells. An in vitro study showed that SK-216 treatment suppressed invasion activity by inhibiting PAI-1 expression in 143B cells, but had no influence on their proliferation or migration. 143B cells treated with SK-216 exhibited reduced matrix metalloproteinase-13 (MMP-13) secretion in a dose-dependent manner. Moreover, intraperitoneal injection of SK-216 into mouse models resulted in downregulation of PAI-1 expression levels in the primary tumors and showed suppression of lung metastases without influencing the proliferative activity of the tumor cells in the primary lesions. These results indicate that SK-216, a PAI-1 inhibitor, may serve as a novel drug to prevent lung metastasis in human osteosarcoma.


PROVIDER: S-EPMC5877597 | BioStudies | 2018-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC4864819 | BioStudies
2013-01-01 | S-EPMC3769403 | BioStudies
1000-01-01 | S-EPMC3129798 | BioStudies
2016-01-01 | S-EPMC5428546 | BioStudies
1000-01-01 | S-EPMC2493014 | BioStudies
2020-01-01 | S-EPMC7281181 | BioStudies
2010-01-01 | S-EPMC2837364 | BioStudies
1000-01-01 | S-EPMC5955096 | BioStudies
2015-08-25 | E-GEOD-55958 | ArrayExpress
2019-01-01 | S-EPMC6420872 | BioStudies